FNCHQ · Finch Therapeutics Group, Inc.
$9.60
+0.00 (+0.00%)
At close · Jul 30
Going-concern doubt
— flagged Aug 13, 2024
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Market Cap
$15.42M
Shares
1.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.60
Open$9.60
Day$9.60–9.60
52W$2.00–16.10
Avg vol 30d1K
Short int392 · 0.0% float · 1.0d
Short vol12%
Last earningsMay 16, 2022
DataMar 2021–Jul 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2024
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.1 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
+7%
above
RSI (14)
45
neutral
MACD trend
Negative
52-week position
54%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−30%
trailing
YTD return
−29%
this year
Relative strength
−39%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $11 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -40.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Squeeze score
28
low risk · 0–100
Fundamentals
Revenue growth
−88%
Y/Y
EPS growth
+35%
Y/Y
Free cash flow
$-31.5M
Balance sheet
$25.1M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
3.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
+7%
Bullish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
54%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $11 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -40.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $2
Now $10 · 54%
52-wk high $16
vs 200-day avg -15%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FNCHQ
this stock
Finch Therapeutics Group, Inc.
|
$15.42M | -28.8% | -87.6% | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$465.49B | +6.0% | +22179.2% | 947.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.26B | +6.3% | +46.2% | 28.6 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.02B | -4.2% | +20.8% | 18.3 | 3.4% |
|
ARGX
Argenx SE
|
$54.59B | +3.8% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FNCHQ | -4.0% | -5.0% | -29.7% | -5.0% | -28.8% |
| SPY | +0.5% | -0.6% | +9.5% | -0.7% | +8.8% |
| vs SPY | -4.5% | -4.4% | -39.1% | -4.3% | -37.6% |